Melissa B. Pappalardi

A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models

Elayne Chan-Penebre, Kristy G. Kuplast, Christina R. Majer et al. · Nature Chemical Biology · 2015 · 533 citations

Vitro Potency, Signal Transduction, Medicine +10

A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC

Helai P. Mohammad, Kimberly N. Smitheman, Chandrashekhar D. Kamat et al. · Cancer Cell · 2015 · 498 citations · Full text

Oncogenic Agent, Medicine, Epigenetic Change +9

Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)

Michael T. McCabe, Alan P. Graves, Gopinath Ganji et al. · Proceedings of the National Academy of Sciences · 2012 · 481 citations · Full text

Histone Modifications, Epigenetic Change, Pathology +20

Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss

Andrew Fedoriw, Satyajit Rajapurkar, Shane W. O’Brien et al. · Cancer Cell · 2019 · 333 citations · Full text

Cancer Research, Mtap Loss, Medicine +10

Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia

Melissa B. Pappalardi, Kathryn Keenan, Mark Cockerill et al. · Nature Cancer · 2021 · 251 citations · Full text

Hematological Malignancy, Medicine, Acute Myeloid Leukemia +9